Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev’s issued and outstanding shares on a share exchange.Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to an enlarged prostate.Medicus will negotiate and enter into a definitive agreement with Antev in exchange for 2.67 million (or approximately ...